As AD tau is hyperphosphorylated at more than 40 sites, it may be beneficial to study combinations of PKIs, or multi-target inhibitors, e.g., a combination of PDPKs and non-PDPKs [39]. The gene discussed is MAPT; the disease is Alzheimer disease.